This webinar will discuss how to use tiered approaches to evaluate the benefits and risks of novel nanomaterials and product formulations containing nanomaterials, as well as common risk mitigation approaches.
Fax: +1-650-362-2367
The FDA is still treating nanomaterials on a case by case basis. How can you determine if the nanotechnology you are considering is safe? FDA applications require proof of safety, as does public perception in an environment where using nanomaterials to improve products still creates fear around unknown aspects of nanotechnology. Responsible commercialization and stewardship require evaluating the potential risks. Yet peer-reviewed literature often appears to have conflicting results as headlines. How can you make scientific sense of this?
This webinar will highlight important fundamental knowledge to enter the nanomaterial risk assessment space, and help you become familiar with measurements of nanomaterials needed to understand what key factors impact or reduce safety risks.
This webinar will enable you to use tiered approaches when performing nanomaterial and product risk assessments; perform better interpretation of NanoEHS literature and identify common mistakes in the literature; and identify risk mitigation approaches for nano enabled products.
Areas Covered in the Webinar:From industries such as Consumer Goods, Medical Devices, Dental Products and Devices, Pharmaceutical Formulation, Cosmetics and more.
Scientist and business leader, Natural Immunogenics Corp
Rob MacCuspie holds a Ph.D. in Nanotechnology and Materials Chemistry, and has twenty years of experience in nanotechnology research, NanoEHS, and responsible commercialization of nano-enabled products. Over his career, he has worked in the National Lab system at the National Institute of Standards and Technology, the Air Force Research Laboratory, and US FDA, as well as being first faculty at Florida Polytechnic University and Director of Nanotechnology and Multifunctional Materials Programs. He holds 1 US patent, has written 42 publications cited over 2,800 times for an h-index of 28.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. FDATrainingAlert would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.
Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.
If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.
We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@fdatrainingalert.com call +1-888-771-6965 (Toll Free).
This product hasn't received any reviews yet. Be the first to review this product! Write review